Retension Pharmaceuticals (NASDAQ:RTSN) Coverage Initiated by Analysts at Zacks Research

Zacks Research assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a research note issued to investors on Wednesday morning,Zacks reports. The brokerage issued a hold rating on the stock.

A number of other equities analysts have also commented on RTSN. Leerink Partners assumed coverage on Retension Pharmaceuticals in a research note on Tuesday. They issued a “strong-buy” rating on the stock. Guggenheim started coverage on shares of Retension Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $55.00 target price for the company. Finally, Oppenheimer began coverage on shares of Retension Pharmaceuticals in a research report on Tuesday. They set an “outperform” rating and a $50.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Retension Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $52.50.

Retension Pharmaceuticals Price Performance

NASDAQ RTSN opened at $10.72 on Wednesday. Retension Pharmaceuticals has a 12 month low of $9.66 and a 12 month high of $18.64.

Insider Buying and Selling at Retension Pharmaceuticals

In other news, CEO Eric L. Keller purchased 20,800 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were acquired at an average price of $12.00 per share, with a total value of $249,600.00. Following the completion of the transaction, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. The trade was a 5.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Franklin M. Berger purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, October 13th. The shares were acquired at an average price of $12.00 per share, with a total value of $120,000.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at approximately $120,000. This trade represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing.

About Retension Pharmaceuticals

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.